It is noteworthy that this risk was no longer present 6 months after the discontinuation of thiopurines and/or switching to anti-TNFα (an adjusted HR 1.22 (95% CI 0.86–1.74, P 5 0.26)), confirming a disbalance between the risk and benefits of continuing AZA after a history of BCC. Here, TNF is linked to skin basal cell carcinoma.